Clinical Proteomics and Molecular Pathology

Molecular Pathology: The Molecular Basis of Human Disease

Volumn 9780123744197, Issue , 2009, Pages 165-183

  Liotta, Lance A ^a   Espina, Virginia ^a   Fredolini, Claudia ^a   Zhou, Weidong ^a   Petricoin, Emanuel ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899928985     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374419-7.00009-3     Document Type: Chapter

References (101)

1. Hunter T Signaling-2000 and beyond. Cell 2000, 100:113-127.
2. Sgroi DC, Teng S, Robinson G, et al. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 1999, 59:5656-5661.
3. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996, 274:998-1001.
4. Banks RE, Dunn MJ, Forbes MA, et al. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis-Preliminary findings. Electrophoresis 1999, 20:689-700.
5. Espina V, Wulfkuhle JD, Calvert VS, et al. Laser capture microdissection. Nature Protocols 2006, 1:586-603.
6. Paweletz CP, Liotta LA, Petricoin EF New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001, 57:160-163.
7. Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 1999, 96:12589-12594.
8. Hancock W, Apffel A, Chakel J, et al. Integrated genomic/proteomic analysis. Anal Chem. 1999, 71:742A-748A.
9. Mann M, Hendrickson RC, Pandey A Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001, 70:437-473.
10. Baak JP, Path FR, Hermsen MA, et al. Genomics and proteomics in cancer. Eur J Cancer 2003, 39:1199-1215.
11. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003, 100:5974-5979.
12. Celis JE, Gromov P Proteomics in translational cancer research: Toward an integrated approach. Cancer Cell 2003, 3:9-15.
13. Gorg A, Weiss W, Dunn MJ Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685.
14. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999, 17:994-999.
15. Krutchinsky AN, Kalkum M, Chait BT Automatic identification of proteins with a MALDI-quadrupole ion trap mass spectrometer. Analytical Chem. 2001, 73:5066-5077.
16. Washburn MP, Wolters D, Yates JR Large scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 2001, 19:242-247.
17. Zhou G, Li H, DeCamp D, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124.
18. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20:1981-1989.
19. Grubb RL, Calvert VS, Wulkuhle JD, et al. Signal pathway profiling of prostate cancer using reverse phase protein microarrays. Proteomics 2003, 3:2142-2146.
20. Gulmann C, Espina V, Petricoin E, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res. 2005, 11:5847-5855.
21. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse-phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005, 4:346-355.
22. Eckel-Passow JE, Hoering A, Therneau TM, et al. Experimental design and analysis of antibody microarrays: Applying methods from cDNA arrays. Cancer Res. 2005, 65:2985-2989.
23. Haab BB Antibody arrays in cancer research. Mol Cell Proteomics 2005, 4:377-383.
24. Humphery-Smith I, Wischerhoff E, Hashimoto R Protein arrays for assessment of target selectivity. Drug Discov World 2002, 4:17-27.
25. MacBeath G, Schreiber SL Printing proteins as microarrays for high-throughput function determination. Science 2000, 289:1760-1763.
26. Petach H, Gold L Dimensionality is the issue: Use of photoaptamers in protein microarrays. Curr Opin Biotechnol. 2002, 13:309-314.
27. Weng S, Gu K, Hammond PW, et al. Generating addressable protein microarrays with PROfusion covalent mRNA-protein fusion technology. Proteomics 2002, 2:48-57.
28. Zhu H, Snyder M Protein chip technology. Curr Opin Chem Biol. 2003, 7:55-63.
29. Leuking A, Cahill DJ, Mullner S Protein biochips: A new and versatile platform technology for molecular medicine. Drug Disc Today 2005, 10:789-794.
30. MacBeath G Protein microarrays and proteomics. Nature Genet. 2002, 32:526-532.
31. Miller JC, Zhou H, Kwekel J, et al. Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers. Proteomics 2003, 3:56-63.
32. Espina V, Wulfkuhle J, Liotta LA, et al. Basic techniques for the use of reverse phase protein microarrays for signal pathway profiling. Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics. Part 3 Proteomics 2005, John Wiley & Sons, West Sussex, UK.
33. LaBaer J, Ramachandran N Protein microarrays as tools for functional proteomics. Curr Opin Chem Biol. 2005, 9:14-19.
34. Espina VA, Edmiston KH, Heiby M, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008, [In Press].
35. Vanmeter AJ, Rodriguez AS, Bowman ED, et al. LCM and protein microarray analysis of human NSCLC: Differential EGFR phosphorylation events associated with mutated EGFR compared to wild type. Mol Cell Proteomics 2008, [In Press].
36. Grote T, Siwak DR, Fritsche HA, et al. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008, 8:3051-3060.
37. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 2003, 100:14229-14234.
38. Liotta LA, Kohn EC, Petricoin EF Clinical proteomics. Personalized molecular medicine. JAMA. 2001, 286:2211-2214.
39. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002, 1:683-695.
40. Liotta L, Petricoin E Molecular profiling of human cancer. Nat Rev Genet. 2000, 1:48-56.
41. Petricoin EF, Bichsel VE, Calvert VS, et al. Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy. J Clin Oncol. 2005, 23:3614-3621.
42. Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003, 3:2085-2090.
43. Sreekumar A, Nyati MK, Varambally S, et al. Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteins. Cancer Res. 2001, 61:7585-7593.
44. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Profiling bladder cancer using targeted antibody arrays. Am J Pathol. 2006, 168:93-103.
45. Zha H, Raffeld M, Charboneau L, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004, 84:235-244.
46. Petricoin EF, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007, 67:3431-3440.
47. Espina V, Dettloff KA, Cowherd S, et al. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther. 2004, 4:83-93.
48. Posadas EM, Davidson B, Kohn EC Proteomics and ovarian cancer: Implications for diagnosis and treatment: A critical review of the recent literature. Curr Opin Oncol. 2004, 16:478-484.
49. Krause DS, Van Etten RA Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005, 353:172-187.
50. Araujo RP, Petricoin EF, Liotta LA A mathematical model of combination therapy using the EGFR signaling network. Biosystems 2005, 80:57-69.
51. Araujo RP, Doran C, Liotta LA, et al. Network-targeted combination therapy: A new concept in cancer treatment. Drug Disc Today 2004, 1:425-433.
52. Arteaga CL, Baselga J Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice. Clin Cancer Res. 2003, 9:1579-1589.
53. Gasparini G, Gion M Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints. Cancer J Sci Am. 2000, 6:117-131.
54. Giaccone G Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005, 23:3235-3242.
55. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350:2129-2139.
56. Paez JG, JȨnne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
57. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003, 21:2237-2246.
58. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003, 290:2149-2158.
59. Bailey R, Kris M, Wolf M, et al. Gefitinib, ("Iressa", ZD1839) monotherapy for pretreated advance non-small cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2003, 41:S71.
60. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advance non-small-cell lung cancer. J Natl Cancer Inst. 2004, 96:1133-1141.
61. Gillespie JW, Best CJ, Bichsel VE, et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 2002, 160:449-457.
62. Mutter GL, Zahrieh D, Liu C, et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics. 2004, 5:88.
63. Becker KF, Schott C, Hipp S, et al. Quantitative protein analysis from formalin-fixed tissues: Implications for translational clinical research and nanoscale molecular diagnosis. J Pathol. 2007, 211:370-378.
64. Espina V, Wulfkuhle J, Calvert VS, et al. Reverse phase protein microarrays for monitoring biological responses. Cancer Genomics and Proteomics: Methods and Protocols 2008, Humana Press, Totowa, NJ, [in press]. P. Fisher (Ed.).
65. Khan IH, Mendoza S, Rhyne P, et al. Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays. Mol Cell Proteomics 2006, 5:758-768.
66. Stone RL, Dixon JE Protein-tyrosine phosphatases. J Biol Chem. 1994, 269:31323-31326.
67. Neel BG, Tonks NK Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 1997, 9:193-204.
68. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
69. Diamandis EP Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics. Clin Chem. 2003, 49:1272-1275.
70. Liotta LA, Petricoin EF Putting the "bio" back into biomarkers: Orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem. 2008, 54:3-5.
71. Liotta LA, Ferrari M, Petricoin E Clinical proteomics: Written in blood. Nature 2003, 425:905.
72. Tirumalai RS, Chan KC, Prieto DA, et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003, 2:1096-1103.
73. Lowenthal MS, Mehta AI, Frogale K, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem. 2005, 51:1933-1945.
74. Zhou M, Lucas DA, Chan KC, et al. An investigation into the human serum "interactome.". Electrophoresis 2004, 25:1289-1298.
75. Lopez MF, Mikulskis A, Kuzdzal S, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem. 2005, 51:1946-1954.
76. Brouwers FM, Petricoin EF, Ksinantova L, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 2005, 12:263-272.
77. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006, 116:271-284.
78. Schulz-Knappe P, Schrader M, Zucht HD The peptidomics concept. Comb Chem High Throughput Screen 2005, 8:697-704.
79. Culp WD, Neal R, Massey R, et al. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res. 2006, 5:1332-1343.
80. Liotta LA, Kohn ED The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
81. Jodele S, Blavier L, Yoon JM, et al. Modifying the soil to affect the seed: Role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006, 25:35-43.
82. Hagendoorn J, Tong R, Fukumura D, et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 2006, 66:3360-3364.
83. Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64:5882-5890.
84. Traub F, Jost M, Hess R, et al. Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest. 2006, 86:246-253.
85. Skates SJ, Horick N, Yu Y, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004, 22:4059-4066.
86. Anderson NL, Anderson NG The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:8458-8467.
87. Deutsch EW, Eng JK, Zhang H, et al. Human plasma peptideatlas. Proteomics 2005, 5:3497-3500.
88. Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005, 5:3467-3474.
89. Hortin GL The MALDI TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem. 2006, 52:1223-1237.
90. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
91. Shen Y, Kim J, Strittmatter EF, et al. Characterization of the human blood plasma proteome. Proteomics 2005, 5:4034-4045.
92. Mehta AI, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2003-2004, 19:1-10.
93. Govorukhina NI, Reijmers TH, Nyangoma SO, et al. Analysis of human serum by liquid chromatography-mass spectrometry: Improved sample preparation and data analysis. J Chromatogr A. 2006, 1120:142-150.
94. Drake RR, Schwegler EE, Malik G, et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006, 5:1957-1967.
95. Gaspari M, Ming-Cheng Cheng M, Terracciano R, et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res. 2006, 5:1261-1266.
96. Terracciano R, Gaspari M, Testa F, et al. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 2006, 6:3243-3250.
97. Yocum AK, Yu K, Oe T, et al. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res. 2005, 4:1722-1731.
98. Luchini A, Geho DH, Bishop B, et al. Smart hydrogel particles: Biomarker harvesting: One-step affinity purification, size exclusion, and protection against degradation. NanoLetters 2008, 8:350-361.
99. Ruoslahti E Specialization of tumour vasculature. Nat Rev Cancer 2002, 2:83-90.
100. Ruoslahti E Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol. 2000, 10:435-442.
101. Akerman ME, Chan WC, Laakkonen P, et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002, 99:12617-12621.